Disruptive Mood Dysregulation Disorder
Disruptive mood dysregulation disorder (DMDD) is a type of childhood condition. Children suffering from it will display sings of extreme irritability, anger as well as frequent temper outbursts. These symptoms go beyond those of a moody child. Children with DMDD need clinical attention lest they suffer severe impairment. This is a relatively new diagnosis, appearing for the first time in 2013 in the Diagnostic and Statistics Manual of Mental Disorders.
The symptoms of disruptive mood dysregulation disorder generally manifest themselves before the age of 10. However, doctors will not put this diagnosis on children under 6 or teenagers over 18. A child with DMDD will:
- Be irritable or angry most of the day, very frequently
- Have severe temper outbursts at around 3 times per week
- Have trouble functioning due to their irritability (in either school, at home, with peers, etc)
To get this diagnosis, the child must have had these symptoms for at least 12 months or more.
You might also like Healing Attachment Disorder In Adults.
Risk Factors of disruptive mood dysregulation disorder
As of now, it is not clear how widespread DMDD is among the general population. However, it is common along the children that visit pediatric mental health clinics. Currently, researchers are looking into the risk factors as well as the brain mechanisms of it.
Since this is a new diagnosis, treatment is based on what has been helpful up until now for irritability and temper tantrums. These disorders also include other symptoms such as ADHD, anxiety disorders and major depressive disorders. If you suspect that your child had DMDD, then seek out treatment immediately. This condition can severely impair your child’s quality of life as well as his performance in school and relationships with others.
The majority of medication that doctors use to treat children and adolescents with mental illnesses work well. They relieve the symptoms and keep them under control. However, some of the medication has not been studied at length by the FDA. Still, the outlook is positive for children that suffer from this condition.